Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Summary
- 2016 Net income per share attributable to common stockholders, $6.76
- "Spherix has no debt and a lower quarterly burn than in the past 4 years."
- "There are five cases on file, working their way through the judicial system."
- "In addition, our efforts with Equitable have secured the monetization rights to over 100 new patents that are largely unlicensed. "
- Hoth anticipates dramatically shorter time frames for FDA approval because the BioLexa compound uses a combination of two previously approved drugs.
- O/S 4.9M
- Market Cap 20M - $4
- Aug 2013 $529 share ; the next $KBIO ?
$SPEX
$ADMP Pre-market: 6.45 +0.70 (+12.17%) FDA approval
Adamis Pharma stock skyrockets after rival EpiPen product gets FDA approval
http://www.marketwatch.com/story/adamis-pharma-stock-skyrockets-after-rival-epipen-product-gets-fda-approval-2017-06-15
$ADMP After Hours: 6.15 +0.40 (6.96%)
Adamis Pharma stock skyrockets after rival EpiPen product gets FDA approval
http://www.marketwatch.com/story/adamis-pharma-stock-skyrockets-after-rival-epipen-product-gets-fda-approval-2017-06-15
$1.2B EpiPen market with their Epinephrine Pre-Filled Syringe product
$ADMP +5.75 +2.00 (53.33%)
After Hours: 6.05 +0.30 (5.22%)
Adamis Pharma stock skyrockets after rival EpiPen product gets FDA approval
http://www.marketwatch.com/story/adamis-pharma-stock-skyrockets-after-rival-epipen-product-gets-fda-approval-2017-06-15
Adamis Pharmaceuticals: Strong Buy Before Huge Potential Catalyst
Window of opportunity is still open for Adamis Pharmaceuticals in the $1.2B EpiPen market with their Epinephrine Pre-Filled Syringe product.
The improved EPI PFS design includes features that should allow it to achieve meaningful penetration in both non-retail and consumer markets.
Mylan’s EpiPen pricing and recall mess over the past year has government and consumers demanding that another viable choice be made available.
Adamis has a growing compounding pharmacy business, strong pipeline, increasing institutional ownership, and is fully funded for the next 9-12 months with recent $17M secondary.
Mid-June PDUFA for EPI PFS presents a strong potential catalyst for the stock.
https://seekingalpha.com/article/4078008-adamis-pharmaceuticals-strong-buy-huge-potential-catalyst
Adamis Pharmaceuticals: Strong Buy Before Huge Potential Catalyst
Window of opportunity is still open for Adamis Pharmaceuticals in the $1.2B EpiPen market with their Epinephrine Pre-Filled Syringe product.
The improved EPI PFS design includes features that should allow it to achieve meaningful penetration in both non-retail and consumer markets.
Mylan’s EpiPen pricing and recall mess over the past year has government and consumers demanding that another viable choice be made available.
Adamis has a growing compounding pharmacy business, strong pipeline, increasing institutional ownership, and is fully funded for the next 9-12 months with recent $17M secondary.
Mid-June PDUFA for EPI PFS presents a strong potential catalyst for the stock.
https://seekingalpha.com/article/4078008-adamis-pharmaceuticals-strong-buy-huge-potential-catalyst
$DCTH up Pre-market: 0.0583 +0.0161 (+38.15%)
$DCTH Pre-market: 0.0583 +0.0161 (+38.15%)
"Accounts after the warrant repurchase will be sufficient to fund our operating activities through the end of 2017."
Dec 31, 2016 137,192,767(5)
Shares Issued 300,000,000 (5)
(5) Restricted Common Stock issued with Legend.
pag 4 http://www.otcmarkets.com/financialReportViewer?symbol=POTN&id=173965
437.192.767 Total Restricted
Float 134,894,135
Note Payable ( Note 4) 1,956,186
(4)Retained Earnings ( First Capital Ventures / Diamond CBD Oils )
so... Relax...
Float only 134,894,135
After Hours: 0.0470 +0.0048 (+11.37%)
$DCTH
Investor Presentation dated June, 2017.
https://www.sec.gov/Archives/edgar/data/872912/000119312517194811/d407690dex991.htm
$DCTH
$DCTH up 95% - 0.0425 - NASDAQ - FDA’s Approval
FDA’s Approval For The Study Design By Delcath Systems, Inc (NASDAQ:DCTH) Sparks Excitement Among The Various Concerned Parties
https://www.wallstreetpr.com/fdas-approval-for-the-study-design-by-delcath-systems-inc-nasdaqdcth-sparks-excitement-among-the-various-concerned-parties-39404
FDA’s Approval For The Study Design By Delcath Systems, Inc (NASDAQ:DCTH) Sparks Excitement Among The Various Concerned Parties
By Chris Brown - June 5, 2017 6280 0
SHARE Facebook Twitter
Delcath Systems, Inc (NASDAQ:DCTH) has moved ahead to state that the Food And Drug Administration has given approval to its design of a clinical trial for its Melphalan/HDS drug product and that is of course in line with Special Protocol Assessment.
As a matter of fact, A Special Protocol Assessment (SPA) happens to be a procedure through which the FDA comes up with an official evaluation and confirmation for a yet-to-be-completed Phase 3 trials design, clinical endpoints, protocols as well as statistical analysis in a bid to form ground for a New Drug Application.
Melphalan/HDS (short for Melphalan Hydrochloride for Injection) which is combined with Delcath’s Hepatic Delivery System, happens to be Delcath’s drug which is specifically designed in a bid to try and administer top and trusted chemotherapy doses to the liver.
As a matter of fact, to this particular point the Melphalan/HDS system hasn’t yet received approval in the U.S, but one thing that is for sure is the fact that it is seen as a combination drug-and-device product.
The agency’s SPA nod has gone ahead to say that the trial design in an adequate way addresses the set goals for evaluating Melphalan/HDS for handling the wide range of patients with intrahepatic cholangiocarcinoma (ICC).According to some close sources, about 295 patients are expected to be enrolled in the global trial at 40 different sites in Europe and in the U.S.
There are hopes that by the fall of 2017 the trial will have kick started and as a matter of fact it will bear the overall survival (OS) as its primary endpoint.
Measures of progression-free survival (PFS), safety as well as overall response rate (ORR) are expected to constitute the wide array of the exploratory and secondary endpoints. It is also important to point to the fact that it isn’t easy to reach the point the provider has reached at the moment since on the way it is usually marred by numerous challenges.
In fact there comes a moment when efforts appear like the drawing of lines in the sand. However, the top notch provider has remained dedicated to coming up with top most solutions and for sure the future looks quite promising.
FDA’s Approval - $DCTH up 95% - 0.0425 - NASDAQ
FDA’s Approval For The Study Design By Delcath Systems, Inc (NASDAQ:DCTH) Sparks Excitement Among The Various Concerned Parties
https://www.wallstreetpr.com/fdas-approval-for-the-study-design-by-delcath-systems-inc-nasdaqdcth-sparks-excitement-among-the-various-concerned-parties-39404
FDA’s Approval For The Study Design By Delcath Systems, Inc (NASDAQ:DCTH) Sparks Excitement Among The Various Concerned Parties
By Chris Brown - June 5, 2017 6280 0
SHARE Facebook Twitter
Delcath Systems, Inc (NASDAQ:DCTH) has moved ahead to state that the Food And Drug Administration has given approval to its design of a clinical trial for its Melphalan/HDS drug product and that is of course in line with Special Protocol Assessment.
As a matter of fact, A Special Protocol Assessment (SPA) happens to be a procedure through which the FDA comes up with an official evaluation and confirmation for a yet-to-be-completed Phase 3 trials design, clinical endpoints, protocols as well as statistical analysis in a bid to form ground for a New Drug Application.
Melphalan/HDS (short for Melphalan Hydrochloride for Injection) which is combined with Delcath’s Hepatic Delivery System, happens to be Delcath’s drug which is specifically designed in a bid to try and administer top and trusted chemotherapy doses to the liver.
As a matter of fact, to this particular point the Melphalan/HDS system hasn’t yet received approval in the U.S, but one thing that is for sure is the fact that it is seen as a combination drug-and-device product.
The agency’s SPA nod has gone ahead to say that the trial design in an adequate way addresses the set goals for evaluating Melphalan/HDS for handling the wide range of patients with intrahepatic cholangiocarcinoma (ICC).According to some close sources, about 295 patients are expected to be enrolled in the global trial at 40 different sites in Europe and in the U.S.
There are hopes that by the fall of 2017 the trial will have kick started and as a matter of fact it will bear the overall survival (OS) as its primary endpoint.
Measures of progression-free survival (PFS), safety as well as overall response rate (ORR) are expected to constitute the wide array of the exploratory and secondary endpoints. It is also important to point to the fact that it isn’t easy to reach the point the provider has reached at the moment since on the way it is usually marred by numerous challenges.
In fact there comes a moment when efforts appear like the drawing of lines in the sand. However, the top notch provider has remained dedicated to coming up with top most solutions and for sure the future looks quite promising.
Investor Presentation dated June, 2017.
https://www.sec.gov/Archives/edgar/data/872912/000119312517194811/d407690dex991.htm
MySize Launches Android Smart Measurement App -- SECFilings.com
REDONDO BEACH, CA -- (Marketwired) -- 06/06/17 -- SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, announces publication of an article discussing MySize Inc.'s (NASDAQ: MYSZ) innovative smartphone measurement applications and the importance of their launch on the Android platform that's significantly larger than the iOS market.
Smart Measurement
MySize has developed a unique measurement technology based on sophisticated algorithms and cutting-edge technology with broad applications across the apparel, e-commerce, and shipping industries. The proprietary technology is driven by several patent-pending algorithms that calculate and record measurements in a variety of novel ways. For example, customers could use the technology to order the correct size of clothing online.
When it comes to the consumer market, the company's flagship SizeUp app is designed to be a valuable utility for smartphones, like the calculator or flashlight. The app enables consumers to instantly and accurately measure all surfaces by placing their smartphone on one side, then lifting it slightly and moving it to the other end, vertically or horizontally. Measurements can also be shared between devices to help make it easier to accomplish household tasks.
Watch a corporate video demonstrating the technology:
Bitcoin companies
Name Symbol Last price Change Mkt cap
Bitcoin Investment Trust GBTC 546.45* +30.45 (5.90%) 964.25M
UBI Blockchain Internet... UBIA 13.90* +3.80 (37.62%) 855.98M
FIRST BITCOIN CAP COM... BITCF 0.400* +0.010 (2.56%) 117.81M
BITCOIN SERVICES I COM... BTSC 0.116* -0.028 (-19.17%) 73M
Global Arena Holding Inc GAHC 0.0554* +0.0014 (2.61%) 18M
The patent that GAHC owns is unique, and the other crypto companies that use them, will have to pay to use it in their operations.
Global Arena Big Plan
In a bid to take advantage of the growth in demand for blockchain technology and Bitcoin, Global Arena has already started to work on its own type of applications that leverage the two. Such applications involve applying blockchain in ATM machines, smart contracts, wills, and even voting machines.
Getting a head start on this application is key if a technology company is to stand a chance in competing against other companies with huge financial muscles. As bitcoin and blockchain become more mainstream Global Arena Holding Inc. (OTCMKTS:GAHC) could be able to generate a substantial amount of revenues.
http://stocknewsunion.com/global-arena-holding-inc-otcmktsgahc-in-focus-as-bitcoin-continues-to-rise/5432/
cryptocurrency market cap reached $96.5 billion ; bitcoin price doubling again to around $6000
The cryptocurrency market is expanding rapidly in recent years. According to the data from Coinmarketcap.com, the total cryptocurrency market cap reached $96.5 billion this year. Bitcoin , one of the most popular cryptocurrencies, and it has increased in value 5.2 percent to $2,650 a coin on Monday. Bitcoin had already gained 157 percent year-to-date and dominated the cryptocurrency market with $43 billion market cap. Another digital currency, Ethereum, also skyrocketed this year. The price of Ethereum hit a new record high of $250.41 a coin on Sunday, with an increase of more than 2800 percent this year. Ethereum now the second-most popular cryptocurrency and is gaining market share rapidly.
"There is a lot of fresh liquidity flowing into bitcoin, thanks to a surge in interest among investors in Asia , notably Japan and Korea , coupled with a resolution to the scaling debate. I would not be surprised to see the bitcoin price doubling again to around $6000 by the end of the year," Aurelien Menant , CEO of Gatecoin, a regulated cryptocurrency exchange, said in a CNBC interview.
BTC/USD 2,905.0 +215.0 +7.99%
BTC/USD 2,742.0 +52.0 +1.93%
KEY Blockchain Patent Grant GAHC 2017 P2P VERITESEUM LIKE?
https://ih.advfn.com/videos/stock-research/key-blockchain-patent-grant-gahc-2017-p2p-veriteseum-like_Hy0OMNrf-qw
Shared By : Cryptobank
Symbol : GAHC
Category : Stock Research
Description :This small Brooklyn startup was first to conceive, first to prototype and first to file patent protection for the capital markets application of blockchain technology. See what we're looking for in investors.
Blockchain Patent !
P2P BLOCKCHAIN BIGGER THAN BITCOIN ONLY - NEW Video
https://ih.advfn.com/videos/educational/p2p-blockchain-bigger-than-bitcoin-only_28294f8GTM0
The reason is the market capitalization, it's the lowest, there's a lot more to go up ...
GAHC - 0.054
Market Value $17 M
Outstanding Shares 331,352,371
other Bitcoin companies:
BTSC - 0.143
Market Value $90 M
Authorized Shares 1,770,000,000 a/o Mar 02, 2017
Outstanding Shares 632,836,771 a/o Mar 02, 2017
___________________________________
GBTC - 516.00
Market Value $948 M
Outstanding Shares 1,837,300
____________________________________
UBIA - 10.10
Market Value1 $305 M
Authorized Shares 200,000,000 a/o Apr 28, 2017
Outstanding Shares 30,217,046 a/o Apr 28, 2017
BTC/USD 2,660.0 +124.0 +4.89%
UBI Blockchain Internet Ltd(OTCBB:UBIA)
Today increases 130M in capitalization.
Then, everything is possible.
$GAHC
Global Arena Holding has two subsidiary companies – one called GAHI Acquisition Corp and one called Global Election Services. The former was set up to serve as a moniker through which Global Arena could operate crypto type business – specifically, through the application of the blockchain (the technology framework that underpins bitcoin) to various different areas of tech and finance.
The thing to realize in this space is that it’s blockchain that is the game changer – not bitcoin. Bitcoin is a currency that uses the principles of the blockchain (and uses its own blockchain) to operate and function. The blockchain concept, however, can be applied to pretty much anything that can benefit from time stamped data.
That’s a big list, of course, and Global Arena is trying to bring a few of its own blockchain type applications to market. It’s doing so through a brand of its GAHI sub called Blockchain Technologies Corp (BTC), and as per the most recent communication, BTC is working on applying the blockchain to the notary space, smart contracts and wills, ATM machines and – and this one’s of note – voting. The latter, of course, fits in nicely with the company’s other sub, Global Election Services, and therein lies the synergy between the two arms of operation. Lots of other companies are working to apply blockchain to smart contracts, and ATMs, etc., most of which are more advanced in their efforts than Global Arena. If the company can get its voting technology off the ground, however, it could be a real winner. Anything from shareholder voting to elections can benefit, and the company is already established in this space – it just needs to adapt its Election Services operation to incorporate blockchain, and it’s up and running.
Bitcoin $GAHC - Potential 10 bagger or more
GAHC - 0.04
Market Value $13 M
Outstanding Shares 331,352,371
other Bitcoin companies:
BTSC - 0.16
Market Value $101 M
Authorized Shares 1,770,000,000 a/o Mar 02, 2017
Outstanding Shares 632,836,771 a/o Mar 02, 2017
___________________________________
GBTC - 518.00
Market Value $951 M
Outstanding Shares 1,837,300
____________________________________
UBIA - 7.21
Market Value1 $217 M
Authorized Shares 200,000,000 a/o Apr 28, 2017
Outstanding Shares 30,217,046 a/o Apr 28, 2017
GAHC - Potential 10 bagger or more Bitcoin
GAHC - 0.04
Market Value $13 M
Outstanding Shares 331,352,371
other Bitcoin companies:
BTSC - 0.16
Market Value $101 M
Authorized Shares 1,770,000,000 a/o Mar 02, 2017
Outstanding Shares 632,836,771 a/o Mar 02, 2017
___________________________________
GBTC - 518.00
Market Value $951 M
Outstanding Shares 1,837,300
____________________________________
UBIA - 7.21
Market Value1 $217 M
Authorized Shares 200,000,000 a/o Apr 28, 2017
Outstanding Shares 30,217,046 a/o Apr 28, 2017
GAHC - 0.04
Market Value $13 M
Outstanding Shares 331,352,371
other Bitcoin companies:
BTSC - 0.16
Market Value $101 M
Authorized Shares 1,770,000,000 a/o Mar 02, 2017
Outstanding Shares 632,836,771 a/o Mar 02, 2017
___________________________________
GBTC - 518.00
Market Value $951 M
Outstanding Shares 1,837,300
____________________________________
UBIA - 7.21
Market Value1 $217 M
Authorized Shares 200,000,000 a/o Apr 28, 2017
Outstanding Shares 30,217,046 a/o Apr 28, 2017
BTC/USD 2,600.00 +64.03 +2.52%
Name Symbol Last price Change Mkt cap?
Bitcoin Investment Trust GBTC 522.50* +22.50 (4.50%) 934M
UBI Blockchain Internet... UBIA 8.04* +2.10 (35.35%) 347M
BITCOIN SERVICES I COM... BTSC 0.124* +0.010 (9.21%) 78M
Global Arena Holding Inc GAHC 0.0334* +0.0074 (28.46%) 11M
Do not forget this!
10/20/30 bagger at these prices!
Video 7 hours ago
KEY Blockchain Patent Grant GAHC 2017 P2P VERITESEUM LIKE?
https://ih.advfn.com/videos/stock-research/key-blockchain-patent-grant-gahc-2017-p2p-veriteseum-like_Hy0OMNrf-qw
Shared By : Cryptobank
Symbol : GAHC
Category : Stock Research
Description :This small Brooklyn startup was first to conceive, first to prototype and first to file patent protection for the capital markets application of blockchain technology. See what we're looking for in investors.
Forget it and focus on the essentials:
GAHC is much better than BTSC; Comparing:
O/S: GAHC 343M May 30 v BTSC 632M Mar 02
A/S: GAHC 1B v BTSC 1.77B
Market Value: GAHC 8M v BTSC 72M